Head-to-head · WeighScore
DoctorAdam vs NuuVim
By GLP-1 ScorecardUpdated
Score comparison
DoctorAdam has the higher recorded score — 75.9/100 to 70.6/100.
DoctorAdam grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. DoctorAdam publishes starting prices by formulation and describes separate refund deadlines for initial and automatic orders.
Before you choose
Before comparing the headline prices, the DoctorAdam review and the NuuVim review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, DoctorAdam vs Strut Health and ElixaMD vs NuuVim compare each of them with another graded program, and the list of alternatives to DoctorAdam ranks the programs closest to DoctorAdam on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | DoctorAdam | NuuVim |
|---|---|---|
| WeighScore | 75.9/100 | 70.6/100 |
| Grade | C | C |
| Site position | #55 | #113 |
| Semaglutide | From $129 advertised; confirm formulation, quantity and total | $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide | Tablets from $199; injections from $229; confirm selected charge | $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Coverage | Confirm availability for your state and prescription | Coverage not published |
| Brand-name access | Not confirmed | Yes |
| Oral / sublingual | Yes | Yes |
Strengths
- Lists separate tablet and injection prices
- Written policy describes a 48-hour refund window for optional Autocharge orders
- Policy promises a refund when a declined prescription request leaves an order unfulfilled
What to consider
- Starting prices leave the selected quantity and total open
- Initial and manual orders have a separate refund cutoff
- Confirm the selected treatment is available in your state
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
What to consider
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.